Global Information
회사소개 | 문의 | 비교리스트

세계의 액체생검 시장(2021년)

The World Liquid Biopsy Market 2021

리서치사 Kalorama Information
발행일 2021년 12월 상품코드 1044144
페이지 정보 영문 228 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 5,000 ₩ 6,358,000 Online Access (Single User License)
US $ 7,500 ₩ 9,537,000 Online Access & PDF Download (10 Users)
US $ 10,000 ₩ 12,717,000 Online Access & PDF Download (Unlimited Users)


세계의 액체생검 시장(2021년) The World Liquid Biopsy Market 2021
발행일 : 2021년 12월 페이지 정보 : 영문 228 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

액체생검 검사는 임상 종양학의 측면에서 많은 응용이 기대되고 있습니다.

세계의 액체생검(Liquid Biopsy) 시장에 대해 조사했으며, 시장 개요와 함께 분석물별, 용도별, 암 종류별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 주요 요약

  • 서론
  • 액체생검 기술
  • 업계 구조
  • 액체생검 시장 매출과 예측

제2장 액체생검 기술

  • 서론
  • 현재 주요 액체생검 기술

제3장 순환 종양 DNA(CTDNA) 액체생검

  • 서론
  • 액체생검에서 CTDNA의 이점과 제한
  • 현재 CTDNA 기반 액체생검 테스트
  • 개발중인 CTDNA 기반 액체생검 테스트

제4장 순환종양세포(CTCS) 액체생검

  • 서론
  • CTC 기반 액체생검 테스트 개발의 과제
  • CTC 기반 액체생검 테스트
  • 개발중인 CTC 기반 액체생검 테스트

제5장 세포외소포 및 기타 액체생검

  • 서론
  • 세포외소포/기타 분석물 기반 액체생검 테스트
  • 개발중인 세포외소포/기타 분석물 기반 액체생검 테스트

제6장 다중 분석물 액체생검 테스트

  • 서론
  • 다중 분석물 기반 액체생검 테스트
  • 개발중인 다중 분석물 기반 액체생검 테스트

제7장 조사 목적으로만 사용되는 액체생검 테스트

  • 서론
  • 조사 목적으로만 사용되는 액체생검 테스트

제8장 액체생검 업계 분석

  • 서론
  • 경쟁 구조
  • 경쟁 요인
  • 중요한 시장 동향
  • 맞춤형 의료
  • 세계의 평균여명 증가
  • 새로운 액체생검 제품
  • 유전자 검사의 접근성 향상
  • 규제 장애
  • 서드파티 지불인의 보상 범위
  • 실증된 임상적 유용성
  • 특정 암 발생률
  • 액체생검 시장의 경쟁사

제9장 액체생검 시장

  • 시장 개요
  • 시장 예측

제10장 분석물별 시장

  • 순환 종양 DNA
  • 순환종양세포
  • 세포외소포 및 기타 분석물
  • 다중 분석물

제11장 용도별 시장

  • 치료 가이던스와 모니터링
  • 진단/스크리닝
  • 질환 예후

제12장 암 종류별 시장

  • 유방암
  • 대장암
  • 폐암
  • 난소암
  • 전립선암
  • 기타

제13장 액체생검 기업 개요

  • 액체생검 시장의 주요 기업 10개사
    • ADAPTIVE BIOTECHNOLOGIES
    • AGENA BIOSCIENCE, INC
    • ANGLE, PLC
    • ASPIRA WOMEN'S HEALTH
    • BIOCARTIS GROUP NV
    • BIOCEPT, INC
    • BIODESIX
    • CELLMAX LIFE
    • CIRCULOGENE
    • DIACARTA, INC
    • EPIC SCIENCES
    • EPIGENOMICS AG
    • EXACT SCIENCES
    • EXOSOME DIAGNOSTICS, INC
    • FOUNDATION MEDICINE, INC(ROCHE)
    • FREENOME, INC
    • GILUPI GMBH
    • GRAIL
    • GUARDANT HEALTH, INC
    • HOLOGIC
    • LUNGLIFE AI
    • MDXHEALTH
    • MENARINI-SILICON BIOSYSTEMS, SPA
    • MYRIAD GENETICS, INC
    • NATERA, INC.
    • NEOGENOMICS LABORATORIES, INC.
    • ONCOCYTE CORPORATION
    • ONCODNA SA
    • ONCIMMUNE
    • PERSONAL GENOME DIAGNOSTICS
    • PREDICINEQ2 SOLUTIONSQIAGEN N.V.
    • Cell-free DNA Technologies
    • CTC Technologies
    • Exosome and miRNA Technologies
    • RESOLUTION BIOSCIENCES(AGILENT)
    • ROCHEDIAGNOSTICS
    • STAGEZERO LIFE SCIENCES
    • SYSMEX-INOSTICS, INC.
    • TEMPUS
    • VERACYTE
    • VOLITIONRX
KSM 22.02.15

This report, “The World Liquid Biopsy Market, 2021 ”, from Kalorama Information, contains up-to-date information and useful data points for business planning:

  • Research vs. Clinical Liquid Biopsy
  • The Market for Liquid Biopsy by Region
  • The Market for Liquid Biopsy Market by Type of Analyte
  • The Market for CTC-based Liquid Biopsy
  • The Market for ctDNA-based Liquid Biopsy
  • The Market for EV and Exosome-based Liquid Biopsy
  • The Market for Multi-Analyte-based Liquid Biopsy
  • The Market for Other Liquid Biopsy
  • Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
  • Selected ctDNA-based Liquid Biopsy Tests in Development
  • Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
  • Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021

While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

  • Early detection and diagnosis / screening
  • Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
  • Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
  • Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
  • Prognosis of disease

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • INTRODUCTION
  • LIQUID BIOPSY TECHNOLOGIES
  • INDUSTRY STRUCTURE
  • LIQUID BIOPSY MARKET REVENUES AND FORECAST
    • Figure 1-1: Global Liquid Biopsy Market by Geographic Region, 2021 (%)
    • Table 1-1: Global Liquid Biopsy Market Forecast, by Region ($ millions), 2021-2026
    • Figure 1-2: Global Liquid Biopsy Market Forecast by Region $ millions), 2021-2026

CHAPTER 2: LIQUID BIOPSY TECHNOLOGIES

  • INTRODUCTION
    • Table 2-1: Comparison of Tissue and Liquid Biopsy
  • CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES
    • Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies

CHAPTER 3: CIRCULATING TUMOR DNA (CTDNA) LIQUID BIOPSY

  • INTRODUCTION
  • ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
  • CURRENT CTDNA-BASED LIQUID BIOPSY TESTS
    • Table 3-1: Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2021
  • Biocartis
  • Biocept
  • Biodesix
  • CellMax Life
  • Circulogene
  • Diacarta
  • Epigenomics
  • Foundation Medicine (Roche)
  • Guardant Health
  • Inivata (Neogenomics)
  • LungLife AI
  • Myriad Genetics
  • NeoGenomics
  • OncoDNA
  • Personal Genomic Diagnostics
  • QIAGEN
  • Resolution Biosciences
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus
  • CTDNA-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development
  • Exact Sciences
  • Freenome
  • GRAIL
  • Neogenomics

CHAPTER 4: CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY

  • INTRODUCTION
  • CHALLENGES IN THE DEVELOPMENT OF CTC-BASED LIQUID BIOPSY TESTS
  • CTC-BASED LIQUID BIOPSY TESTS
    • Table 4-1: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
  • Adaptive Biotechnologies
  • Biocept
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
  • CTC-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2021
  • ANGLE
  • Epic Sciences
  • Liquid Biotech USA

CHAPTER 5: EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY

  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES / OTHER ANALYTES
    • Table 5-1: Selected Market-Available Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2021
  • Aspira Women's Health (formerly Vermillion)
  • Biodesix
  • Exosome Diagnostics
  • Hologic
  • MDxHealth
  • EXTRACELLULAR VESICLE/OTHER ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2021
  • Circulogene
  • OncoCyte
  • Resolution Biosciences
  • VolitionRx

CHAPTER 6: MULTI-ANALYTE LIQUID BIOPSY TESTS

  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON MULTIPLE ANALYTES
    • Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021
  • Biocept
  • Biodesix
  • Foundation Medicine (Roche)
  • LungLife AI
  • NeoGenomics
  • OncoDNA
  • MULTIPLE ANALYTE-BASED LIQUID BIOPSY TESTS IN DEVELOPMENT
    • Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2021
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

CHAPTER 7: LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY

  • INTRODUCTION
  • LIQUID BIOPSY TESTS FOR RESEARCH USE ONLY
    • Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2021
  • Agena Bioscience
  • ANGLE
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • Natera
  • QIAGEN

CHAPTER 8: LIQUID BIOPSY INDUSTRY ANALYSIS

  • INTRODUCTION
  • TIERS OF COMPETITION
    • Table 8-1: Selected Participants in the Liquid Biopsy Market, 2021
  • COMPETITIVE FACTORS
  • SIGNIFICANT MARKET TRENDS
    • Table 8-2: Significant Trends in the Liquid Biopsy Market, 2021
  • Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers
  • COMPETITORS NO LONGER IN THE LIQUID BIOPSY MARKET
    • Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market

CHAPTER 9: LIQUID BIOPSY MARKET

  • MARKET OVERVIEW
    • Figure 9-1: Global Liquid Biopsy Diagnostics Market Estimate by Analyte, 2021 (%)
    • Figure 9-2: Global Liquid Biopsy Diagnostics Market Estimate by Region, 2021 (%)
    • Figure 9-3: Global Liquid Biopsy Market Estimate by Type of Use, (Research Use, Clinical Diagnostics Use) 2018 (%)
  • MARKET FORECAST
    • Table 9-1: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World, World ($ millions), 2021-2026
    • Figure 9-4: Global Liquid Biopsy Market Forecast by Region - North America, Europe, Asia Pacific, Rest of World ( $ millions), 2021-2026

CHAPTER 10: MARKET BY ANALYTE

  • CIRCULATING TUMOR DNA
    • Market Overview
    • Applications
    • Technologies
    • Specimens
    • Revenue Forecast
      • Table 10-1: Global Liquid Biopsy Market for ctDNA ($ millions), 2021-2026
  • CIRCULATING TUMOR CELLS
    • Market Overview
    • Applications
    • Technologies
    • Specimens
    • Revenue Forecast
      • Table 10-2: Global Liquid Biopsy Market for CTCs ($ millions), 2021-2026
  • EXTRACELLULAR VESICLES AND OTHER ANALYTES
    • Market Overview
    • Applications
    • Technologies
    • Specimens
    • Revenue Forecast
      • Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles ($ millions), 2021-2026
  • MULTIPLE ANALYTES
    • Market Overview
    • Revenue Forecast
      • Table 10-4: Global Liquid Biopsy Market for Multiple Analytes ($ millions), 2018-2023

CHAPTER 11: MARKET BY APPLICATION

  • THERAPY GUIDANCE AND MONITORING
    • Market Overview
    • Revenue Forecast
      • Table 11-1: Liquid Therapy for Therapy Guidance ($ millions), 2021-2026
  • DIAGNOSIS/SCREENING
    • Market Overview
    • Revenue Forecast
      • Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening ($ millions), 2021-2026
  • DISEASE PROGNOSIS
    • Market Overview
    • Revenue Forecast
      • Table 11-3: Global Liquid Biopsy Market for Disease Prognosis ($ millions), 2021-2026

CHAPTER 12: MARKET BY CANCER TYPE

  • BREAST CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-1: Global Liquid Biopsy Market for Breast Cancer ($ millions), 2021-2026
  • COLORECTAL CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer ($ millions), 2021-2026
  • LUNG CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-3: Global Liquid Biopsy Market for Lung Cancer ($ millions), 2021-2026
  • OVARIAN CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer ($ millions), 2021-2026
  • PROSTATE CANCER
    • Market Overview
    • Revenue Forecast
      • Table 12-5: Global Liquid Biopsy Market for Prostate Cancer ($ millions), 2021-2026
  • OTHER CANCERS
    • Market Overview
    • Revenue Forecast
      • Table 12-6: Global Liquid Biopsy Market for Other Cancers ($ millions), 2021-2026

Notes: *Including bladder, gastrointestinal, pancreatic, renal, melanoma and hematological malignancies.

  • PAN-CANCER TESTS
    • Market Overview
    • Revenue Forecast
      • Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing ($ millions), 2021-2026

CHAPTER 13: LIQUID BIOPSY COMPANY PROFILES

  • TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET
    • Table 13-1
  • Top Ten Companies in the Liquid Biopsy Market
    • ADAPTIVE BIOTECHNOLOGIES
    • AGENA BIOSCIENCE, INC.
    • ANGLE, PLC
    • ASPIRA WOMEN'S HEALTH
    • BIOCARTIS GROUP NV
    • BIOCEPT, INC.
    • BIODESIX
    • CELLMAX LIFE
    • CIRCULOGENE
    • DIACARTA, INC.
    • EPIC SCIENCES
    • EPIGENOMICS AG
    • EXACT SCIENCES
    • EXOSOME DIAGNOSTICS, INC.
    • FOUNDATION MEDICINE, INC. (ROCHE)
    • FREENOME, INC.
    • GILUPI GMBH
    • GRAIL (ILLUMINA)
    • GUARDANT HEALTH, INC.
    • HOLOGIC
    • LUNGLIFE AI (FORMERLY CYNVENIO BIOSYSTEMS)
    • MDXHEALTH
    • MENARINI-SILICON BIOSYSTEMS, SPA
    • MYRIAD GENETICS, INC.
    • NATERA, INC.
    • NEOGENOMICS LABORATORIES, INC.
    • ONCOCYTE CORPORATION
    • ONCODNA S.A.
    • ONCIMMUNE
    • PERSONAL GENOME DIAGNOSTICS
    • PREDICINEQ2 SOLUTIONSQIAGEN N.V.
    • Cell-free DNA Technologies
    • CTC Technologies
    • Exosome and miRNA Technologies
    • RESOLUTION BIOSCIENCES (AGILENT)
    • ROCHE DIAGNOSTICS
    • STAGEZERO LIFE SCIENCES
    • SYSMEX-INOSTICS, INC.
    • TEMPUS
    • VERACYTE
    • VOLITIONRX
Back to Top
전화 문의
F A Q